Thrombolytic action of ticlopidine: possible mechanisms

Gryglewski, Ryszard J.; Korbut, Ryszard; Swieş, J; Kostka-Trabka, E; Bieroń, K; Robak, J

doi:10.1016/0014-2999(96)00256-7

Cited by 41 publications

(23 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 In addition, in vitro data with ticlopidine, a thienopyridine derivative similar to clopidogrel, have been shown to induce thrombolysis in patients with peripheral artery disease. 13 The authors theorize that the immediate thrombolytic effects of this medication class are independent of their anti-platelet properties, and rather, are due to the ability of the non-metabolized compounds to generate endogenous tissue plasminogen activator and prostacyclin.…”

Section: Discussionmentioning

confidence: 99%

An Alternative Treatment Strategy for Pump Thrombus in the DeBakey VAD Child: Use of Clopidogrel as a Thrombolytic Agent

Studer

Kennedy

Dreyer

et al. 2006

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

An Alternative Treatment Strategy for Pump Thrombus in the DeBakey VAD Child: Use of Clopidogrel as a Thrombolytic Agent

Studer

Kennedy

Dreyer

et al. 2006

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

“…Ticlopidine might exert an immediate thrombolytic effect separate from its delayed antiplatelet action, possibly through the release of endothelial prostacyclin and/or tissue plasminogen activator. 13 Kawasaki disease is known to be associated with a state of hypercoagulability and platelet activation, which can persist for weeks after the onset of fever. 14 It is most likely that, during the period after the failure of t-PA and streptokinase, as the patient recovered from a hypercoagulable state, ticlopidine may have prevented further thrombosis and allowed the LAD thrombus to be lysed by intrinsic fibrinolytic activity.…”

Section: Discussionmentioning

confidence: 99%

Ticlopidine Plus Aspirin for Coronary Thrombosis in Kawasaki Disease

O’Brien

Parness²,

Neufeld³

et al. 2000

Pediatrics

View full text Add to dashboard Cite

ABSTRACT. Selective inhibitors of the adenosine 5-diphosphate pathway of platelet activation have been used rarely in children in the United States. We report the successful use of ticlopidine, together with aspirin, in a 7-month-old infant with Kawasaki disease complicated by a thrombus in a giant coronary aneurysm that failed to resolve with thrombolytic therapy. Pediatrics 2000;105(5). URL: http://www.pediatrics.org/cgi/content/full/105/5/ e64; Kawasaki disease, coronary aneurysms, antithrombotic therapy, ticlopidine, children.ABBREVIATIONS. LAD, left anterior descending coronary artery; IV, intravenous; ADP, adenosine 5Ј-diphosphate.T iclopidine is an antiplatelet drug that has been used in several clinical settings in place of or in combination with aspirin.

show abstract

“…[80] Although this patient did not respond to thrombolytic therapy, the thrombus resolved completely after 3 weeks of ticlopidine. There is evidence that ticlopidine has thrombolytic effects [81] in addition to its effects on platelet aggregation. One of the uncommon but concerning adverse effects of ticlopidine is neutropenia, which may not resolve following discontinuation of the drug.…”

Section: New Antiplatelet Agentsmentioning

confidence: 98%

Pharmacological Therapy for Patients with Kawasaki Disease

2001

View full text Add to dashboard Cite

Kawasaki disease is a systemic vasculitis of unknown aetiology that has been reported worldwide since its initial description in Japanese children. The most significant sequelae of acute Kawasaki disease are related to the inflammation of small to medium sized arteries and, in particular, the development of coronary artery aneurysms. Because the aetiology is unknown, pharmacological therapy is nonspecific and directed towards modulation of the inflammatory response and inhibition of platelet activation with the aim of preventing coronary artery aneurysms. In the US, the recommended treatment for Kawasaki disease in the acute phase is a single, high dose of intravenous gammaglobulin (2 g/kg) and high dose aspirin (80 to 100 mg/kg/day). Use of this regimen has resulted in a significant decrease in the incidence of coronary artery abnormalities. Although the American Heart Association currently recommends high dose aspirin, moderate doses are used in Japan and the optimal dose of aspirin is not known. There has been renewed interest in the use of corticosteroids in the treatment of acute Kawasaki disease: however, their precise role remains unclear. Newer antiplatelet agents have also shown some promise in the treatment of patients with coronary artery aneurysms. Long term pharmacological therapy consists primarily of anticoagulation in patients with persistent coronary artery abnormalities. In this review, current recommendations for pharmacological therapy in Kawasaki disease are reviewed and some of the controversies in management of this disease, including management of patients who do not respond to initial therapy and the role of corticosteroids in the acute setting, are outlined.

show abstract

Thrombolytic action of ticlopidine: possible mechanisms

Cited by 41 publications

References 26 publications

An Alternative Treatment Strategy for Pump Thrombus in the DeBakey VAD Child: Use of Clopidogrel as a Thrombolytic Agent

An Alternative Treatment Strategy for Pump Thrombus in the DeBakey VAD Child: Use of Clopidogrel as a Thrombolytic Agent

Ticlopidine Plus Aspirin for Coronary Thrombosis in Kawasaki Disease

Pharmacological Therapy for Patients with Kawasaki Disease

Contact Info

Product

Resources

About